aTYR PHARMA (ATYR) Liabilities and Shareholders Equity (2014 - 2026)

aTYR PHARMA (ATYR) has reported Liabilities and Shareholders Equity for 13 consecutive years, with $69.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity fell 31.23% year-over-year to $69.8 million; the trailing twelve-month figure through Jun 2026 stood at $349.1 million (down 9.84% YoY), and the FY2025 full-year result was $93.0 million, down 3.95% from the prior year.
• Liabilities and Shareholders Equity retreated to $69.8 million in Q2 2026 per ATYR's latest filing, from $79.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $136.8 million in Q1 2023 and bottomed at $69.8 million in Q2 2026.
• Historically, Liabilities and Shareholders Equity has averaged $103.5 million across 5 years, with a median of $99.4 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity surged 95.97% in 2022, then slumped 31.23% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $95.8 million in 2022, then advanced by 25.96% to $120.7 million in 2023, then dropped by 19.75% to $96.8 million in 2024, then fell by 3.95% to $93.0 million in 2025, then fell by 24.92% to $69.8 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $69.8 million, $79.7 million, and $93.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.